Painful Bladder Syndrome Clinical Trial
Official title:
Sensory Processing in Subjects With Painful Bladder Syndrome
The purpose of this study is to determine if clinically relevant subsets exist in patients meeting the diagnosis of Painful Bladder Syndrome (PBS). Subsets suggest differential responses to treatments and if verified, this will be important for the stratification of patients in clinical studies related to PBS.
Status | Completed |
Enrollment | 34 |
Est. completion date | June 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 19 Years to 75 Years |
Eligibility |
Inclusion Criteria: - NIDDK criteria for Painful Bladder Syndrome - Age 19 years or older - Must be able to read and speak English since testing materials are validated in English Exclusion Criteria: - PBS subjects must be independent of co-existing pain disorders or use of medications - Uncontrolled hypertension or significant cardiopulmonary disease - No chronic daily pain - Older than 75 years of age |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Kirklin Clinic Urology Clinic | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | Washington University Early Recognition Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | This study proposes to examine the sensations that are produced by warming the skin, poking the skin, pressure on muscles and by applying a blood pressure cuff. | One and half to two hours. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Recruiting |
NCT02868775 -
A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Not yet recruiting |
NCT01410461 -
Identifying Predictors of Treatment Success in Painful Bladder Syndrome
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Completed |
NCT00672087 -
Diagnostic Challenges in IC (and Male CPPS)
|
||
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT00775281 -
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
|
N/A | |
Completed |
NCT05223244 -
Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC
|
Phase 4 | |
Completed |
NCT02600715 -
Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
|
Phase 4 | |
Completed |
NCT02457182 -
Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Withdrawn |
NCT03027076 -
Microbiome of Urologic Chronic Pelvic Pain Syndrome
|
N/A | |
Completed |
NCT00434343 -
Physical Therapy Trial for Pelvic Pain
|
N/A | |
Terminated |
NCT03143920 -
Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder
|
Early Phase 1 | |
Completed |
NCT02411110 -
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT00194610 -
Botox as a Treatment for Interstitial Cystitis in Women
|
Phase 4 | |
Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
Terminated |
NCT04268810 -
Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis
|
Phase 4 | |
Completed |
NCT01294878 -
Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 3 | |
Terminated |
NCT00451867 -
A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .
|
Phase 3 |